Research Topics
Species | A K GopalSummaryAffiliation: University of Washington Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphomaAjay K Gopal
Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Blood 99:3158-62. 2002..High-dose treatment with (131)I-Tositumomab, etoposide, and cyclophosphamide results in a high remission rate and may provide long-term disease-free survival for patients with relapsed or refractory mantle cell lymphoma...
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantationAjay K Gopal
University of Washington Seattle Cancer Care Alliance, 825 Eastlake Ave E, Seattle, WA 98195, USA
Blood 120:560-8. 2012..Cytomegalovirus was detected in 5 patients (potentially clinically significant in 1). These results support the potential utility of brentuximab vedotin for selected patients with HL relapsing after alloSCT...- The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cellsAjay K Gopal
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington 98195, USA
J Clin Apher 27:81-7. 2012..11 × 10(6) /kg (P < 0.03). A real-time rescue use of plerixafor is feasible and may allow targeted use of this agent. J. Clin. Apheresis, 2012. © 2012 Wiley Periodicals, Inc... 
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbAjay K Gopal
Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA
Blood 112:830-5. 2008....- High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphomaAjay K Gopal
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98195, USA
J Clin Oncol 25:1396-402. 2007..Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites while limiting exposure to normal organs and may be particularly suited for older adults requiring high-dose therapy... - High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experienceAjay K Gopal
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
Cancer 113:1344-50. 2008..We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients... - Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapyAjay K Gopal
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195, USA
Biol Blood Marrow Transplant 12:697-702. 2006..The rationale for incorporation of radioimmunotherapy into reduced intensity allogeneic transplantation regimens for non-Hodgkin lymphoma is discussed, as are current study designs, preliminary results, and future directions... - 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphomaAjay K Gopal
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, USA
Blood 113:5905-10. 2009..5 days, P < .001) compared with controls. These data indicate that the high CD45 expression of T-NHL allows reliable tumor targeting and disease control supporting anti-CD45 RIT for T-NHL patients... - Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumAjay K Gopal
University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Leuk Lymphoma 51:1523-9. 2010..5%) and grade 4 non-hematologic adverse events (n = 2) were rare, with no treatment-related deaths. GCD(R) is a safe and effective outpatient regimen for relapsed lymphoma, and successfully mobilizes PBSCs... - ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphomaAjay K Gopal
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA
Blood 118:1132-9. 2011..The addition of ⁹⁰Y-ibritumomab tiuxetan to NMAT is safe and yields early responses and prolonged disease control in some of the highest-risk B-NHL patients. This trial was registered at www.clinicaltrials.gov as #NCT00119392... - Cranial computed tomography before lumbar puncture: a prospective clinical evaluationA K Gopal
Department of Medicine, Duke University, Durham, NC, USA
Arch Intern Med 159:2681-5. 1999..To prospectively identify which patients can safely undergo lumbar puncture (LP) without screening cranial computed tomography (CT)... - Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancyA K Gopal
Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA
J Clin Oncol 18:1110-5. 2000..To determine the primary sources and secondary complications of Staphylococcus aureus bacteremia (SAB) in cancer patients, as well as predictors of outcome in cancer patients with SAB... - High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysisAjay K Gopal
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
Blood 102:2351-7. 2003..076 at 8 years in the HD-RIT group and.086 at 7 years in the C-HDT group. HD-RIT may improve outcomes versus C-HDT in patients with relapsed FL... - Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanismAjay K Gopal
Seattle Cancer Care Alliance, Mailstop G6 800, Rm 6802, University of Washington, 825 Eastlake Ave E, Seattle, 98109, USA
Blood 103:3516-20. 2004..05). These results establish the efficacy of 4HPR/rituximab combinations, confirm their caspase-mediated mechanism of action, and offer the potential for disease control with minimal toxicity for patients with B-cell malignancies... - Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and olderA K Gopal
Clinical Research Division Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Bone Marrow Transplant 27:593-9. 2001..Optimal conditioning regimen selection may further improve outcome by reducing TRM. Age alone should not be used to exclude patients from receiving myeloablative therapy with ASCT... - Radioimmunotherapy-based conditioning regimens for stem cell transplantationMichelle M Zhang
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
Semin Hematol 45:118-25. 2008.... - Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphomaBrian G Till
Clinical Research Division of Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Leuk Lymphoma 49:1062-73. 2008.... - Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park
Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
Blood 116:4231-9. 2010..0001). Treatment was well tolerated, with no treatment-related mortalities. This study demonstrates the favorable biodistribution profile and excellent therapeutic efficacy attainable with ²¹³Bi-labeled anti-CD20 PRIT... - Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patientsV G Fowler
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
J Am Coll Cardiol 30:1072-8. 1997..The purpose of this prospective study was to examine the role of echocardiography in patients with Staphylococcus aureus bacteremia (SAB)... - Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndromeJohn M Pagel
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Blood 114:5444-53. 2009..This study was registered at www.clinicaltrials.gov as #NCT00008177... - The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphomaR N Pham
Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
Bone Marrow Transplant 40:1039-44. 2007..52, P=0.03), chemoresistance (HR=1.82, P=0.02), > or =2 prior therapies (HR=1.8, P=0.03) and prior radiation (HR=1.99, P=0.003). These data suggest that the histologic grade of FL does not impact PFS or relapse following HDT and ASCT... - Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cellsD Shan
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA 98195, USA
Clin Cancer Res 7:2490-5. 2001..These in vitro findings suggest that the potential in vivo synergy of these well-tolerated drugs may augment the previously demonstrated clinical activity of anti-CD20 monoclonal antibodies in the treatment of B-cell malignancies... - 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remissionJohn M Pagel
Division of Clinical Research, Fred Hutchinson Cancer Research Center D5 380, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109, USA
Blood 107:2184-91. 2006..39-1.08; P = .09). The addition of targeted hematopoietic irradiation to conventional BU/CY is feasible and well tolerated, and phase 2 results are sufficiently encouraging to warrant further study... - A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinationsJohn M Pagel
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 113:4903-13. 2009..We hypothesize that clinical implementation of pretargeted RIT methods will provide a meaningful prolongation of survival for patients with relapsed lymphomas compared with currently available treatment strategies... - Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancyZ Zimmerman
Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, WA 98109 1024, USA
Bone Marrow Transplant 47:804-9. 2012..However, the high non-relapse mortality among previously treated patients, even with reduced-intensity conditioning regimens, indicates that new transplant strategies need to be developed... - Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomasJohn M Pagel
Fred Hutchinson Cancer Research Center, University of Washington, and Aletheon Pharmaceuticals, Inc, Seattle, Washington 98109, USA
Cancer Res 67:5921-8. 2007..Improvements in tumor-to-normal organ ratios of radioactivity cannot be achieved using directly labeled Abs in combination but may be afforded by novel pretargeting methods... - The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantationGrant E Keeney
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA
Leuk Lymphoma 48:1961-7. 2007..82, p = 0.03) after adjusting for FLIPI. These data suggest that the FLIPI and select non-FLIPI factors after adjustment for the FLIPI are associated with survival in FL patients undergoing ASCT... - Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBrian G Till
Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 112:2261-71. 2008..These results show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach. This trial was registered at www.clinicaltrials.gov as #NCT00012207... - Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemiaJohn M Pagel
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
Cancer Res 69:185-92. 2009..These data suggest that pretargeted methods for delivering RIT may be superior to conventional RIT when targeting CD45 for the treatment of leukemia and may allow for the intensification of therapy, while minimizing toxicities... - High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumesJoseph G Rajendran
Department of Radiology, University of Washington, Seattle, Washington 98195, USA
J Nucl Med 45:1059-64. 2004..This study demonstrates the feasibility of using CT to adjust for actual organ volumes in calculating organ-specific absorbed dose estimates... - Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and olderHerschel Wallen
Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Ave N, D3 100, Seattle, WA 98109, USA
J Clin Oncol 23:3439-46. 2005..To evaluate outcomes of ablative allogeneic hematopoietic cell transplantation (HCT) in older patients with hematologic malignancies... - Successful use of full-dose dexamethasone, high-dose cytarabine, and cisplatin as part of initial therapy in non-hodgkin and hodgkin lymphoma with severe hepatic dysfunctionJeanne McCarthy
Department of Pharmacy, University of Washington, Seattle, WA, USA
Clin Lymphoma Myeloma 9:167-70. 2009..The literature on the use of treatment regimens for aggressive lymphoma in the setting of hepatic dysfunction is reviewed... - Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomasAnastasia Pantelias
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
Blood 109:4980-7. 2007..This study highlights the importance of screening the antigenic expression on lymphomas to select the optimal reagent for PRIT... - Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest doseJoseph G Rajendran
Department of Radiology, University of Washington, Seattle, Washington 98195, USA
J Nucl Med 49:837-44. 2008..The goal of each approach is to deliver maximal myeloablative amounts of radioactivity within the tolerance of critical normal organs... - Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primatesDamian J Green
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 114:1226-35. 2009..These results support proceeding to anti-CD45 PRIT clinical trials for patients with both leukemia and lymphoma... - Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantationJaideep Shenoi
Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine from the University of Washington, Seattle, Washington, USA
Curr Opin Oncol 22:143-9. 2010.... - Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapyJohn M Pagel
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 111:2261-8. 2008..These data suggest that anti-CD45 PRIT using an anti-CD45-SA conjugate in a syngeneic murine model of disseminated leukemia may be more effective and less toxic than directly labeled monoclonal antibodies... - Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde
825 Eastlake Ave E, G3 200, Seattle, WA, USA
J Clin Oncol 29:3023-9. 2011.... - Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidenceSandeep Singh
Indian Heart J 57:201-9. 2005 - Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodiesEneida R Nemecek
Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA
Cancer Biother Radiopharm 23:181-91. 2008..We examined an "extracorporeal adsorption therapy" (ECAT) method to remove circulating unbound radioimmunoconjugate and improve the ratios of radiation delivered to B-cells in a macaque model... - Therapeutic use of Rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease)John M Pagel
Am J Hematol 82:1121-2. 2007 - Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell linesShao Xu Ying
Shanghai Sixth Hospital, Shanghai Jiaotong University, Shanghai, China
Leuk Lymphoma 48:1003-14. 2007..These studies add further information to the regulation of programmed cell death in leukemic cells that have to be considered when designing therapeutic strategies...
Research Grants
- OPTIMIZING RADIOIMMUNOTHERAPY FOR NON HODGKIN'S LYMPHOMAAjay Gopal; Fiscal Year: 2005..We anticipate that these interventions will ultimately enhance the prognosis for patients with relapsed lymphoma by increasing the response and survival rates, while simultaneously minimizing toxicities. ..
- Proapoptotic Therapy for B-cell Non Hodgkin's LymphomaAjay Gopal; Fiscal Year: 2007..The results of this project will be critical to the future development of this therapy and potentially lead to a novel, practical, inexpensive, well-tolerated, oral method to optimize the efficacy of anti-CD20 therapy for B-NHL. ..